BEIJING, Oct. 25, 2024 /PRNewswire/ — Technological advancements have profoundly transformed the global governance system, making the protection of emerging rights…
CARMIEL, Israel, Oct. 25, 2024 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization…
JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally administered, brain penetrant inhibitor of…